Outlook: Nice, but what's in it for shareholders?
Thursday 10 December 1998
Furthermore, both companies face a severe patent expiry problem early in the next century. Perhaps as much as 60 per cent of present sales are affected. Obviously there are replacement products coming through to help fill the hole, but it almost certainly wishful thinking to believe, as Sir David Barnes seems to, that AstraZeneca will soon be challenging Glaxo Wellcome in product development and market reach.
Hakan Mogren, the portly former chocolate factory manager who runs Astra, gets his long sought after passport out of Stockholm (oh how the Swedes do like London) while Percy Barnevik is delivered another management challenge to get his teeth into. And the deal partially solves the problem of management succession at Zeneca. But what's in it for shareholders?
Individually, both companies are just about bite-for the goliaths, but together they are too big to swallow. It can readily be seen that if the merger fails to deliver the promised new force in global pharmaceuticals, it will destroy shareholder value, not create it. Both share prices rose strongly yesterday, but this was less of a thumbs up for the merger as a recognition of the opportunity it creates for others to swoop. We can probably safely rule out Glaxo Wellcome. Much as it would like to take out Zeneca, the scale of the job cuts it would have to push through to make the takeover pay would make it politically unacceptable. But a company such as Roche might be interested in either Zeneca or Astra. Nor would other foreign players have any such qualms over British job losses.
With so many other big mergers in the regulatory mangle, including two other giant pharmaceutical get togethers, this deal could take as long as nine months to clear. That allows plenty of time for rival proposals to come forward.
Harry Potter actor suffered 'severe flu-like symptoms' on a flight from London to Orlando
Rap music mogul accused of running two men over in his truck
World cities ranked in terms of safety, food security and 'liveability'
First full-length look is finally here
"Oink! Oink! Hee hee hee!" First interview with the big-screen star
Biohacking group hopes technology will lead people to think about even more dystopian uses
The party's potential nominations read like a high school race for student body president
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Mia Khalifa: Pornhub star claims Drake sent her 'cringeworthy' naked photos on Instagram
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...